PANews reported on January 7th that, according to CoinDesk, former Central Bank of Brazil director Tony Volpon has launched BRD, a yield-sharing stablecoin peggedPANews reported on January 7th that, according to CoinDesk, former Central Bank of Brazil director Tony Volpon has launched BRD, a yield-sharing stablecoin pegged
A former Brazilian central bank official launched BRD, a stablecoin pegged to the real exchange rate and with shared profits.
PANews reported on January 7th that, according to CoinDesk, former Central Bank of Brazil director Tony Volpon has launched BRD, a yield-sharing stablecoin pegged to the Brazilian currency and backed by Brazilian government debt. Volpon stated on CNN Brazil's "Cripto na Real" program that the token will be supported by national bonds, linking its value to sovereign debt, aiming to allow holders to enjoy the benefits of local interest rates. The Central Bank of Brazil's benchmark interest rate is 15%, while the Federal Reserve's target interest rate is 3.5% to 3.75%.
Volpon stated that this move aims to make it easier for foreign investors to access Brazil's high-yield environment. Although Brazil's interest rates have long attracted international attention, access to these yields has often been limited due to factors such as regulatory restrictions, currency frictions, and domestic infrastructure. BRD may increase demand for the country's debt and potentially lower borrowing costs by expanding the investor base.
Market Opportunity
Lorenzo Protocol Price(BANK)
$0.04985
$0.04985$0.04985
USD
Lorenzo Protocol (BANK) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
You May Also Like
5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale
BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze
The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution
The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26